Paul Tudor Jones’s Clovis Oncology, Inc. CLVS Stock Holding History

Paul Tudor Jones’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,110	Closed	-$22K	–	2639
2022 Q1	$22K	Sell	11,110 -23,321	-68%	-$45.8K	﹤0.01%	1900
2021 Q4	$93K	Buy	+34,431	New	+$127K	﹤0.01%	2237
2021 Q3	–	Sell	-331,063	Closed	-$1.92M	–	2934
2021 Q2	$1.92M	Buy	331,063 +303,196	+1,088%	+$1.78M	0.04%	580
2021 Q1	$196K	Buy	+27,867	New	+$187K	﹤0.01%	1438
2020 Q3	–	Sell	-11,934	Closed	-$81K	–	1613
2020 Q2	$81K	Buy	+11,934	New	+$90.4K	﹤0.01%	1094
2020 Q1	–	Sell	-66,634	Closed	-$695K	–	1411
2019 Q4	$695K	Buy	+66,634	New	+$485K	0.03%	618
2019 Q3	–	Sell	-53,849	Closed	-$801K	–	1413
2019 Q2	$801K	Buy	+53,849	New	+$973K	0.02%	571
2018 Q1	–	Sell	-5,868	Closed	-$399K	–	1320
2017 Q4	$399K	Buy	+5,868	New	+$410K	0.01%	691
2016 Q2	–	Sell	-13,858	Closed	-$266K	–	2011
2016 Q1	$266K	Sell	13,858 -211,142	-94%	-$4.47M	0.01%	1360
2015 Q4	$7.88M	Buy	225,000 +220,869	+5,347%	+$14.2M	0.22%	69
2015 Q3	$380K	Buy	+4,131	New	+$358K	0.01%	957

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Paul Tudor Jones's CLVS Position: Q2 2022 in Review

Paul Tudor Jones sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 11,110 shares — an estimated $22K sold.

Paul Tudor Jones first reported a position in CLVS in Q3 2015 and held it in 11 quarters. The position peaked at $7.88M in Q4 2015. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Paul Tudor Jones reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Paul Tudor Jones sold 11,110 Clovis Oncology, Inc. shares in Q2 2022, an estimated $22K.
Paul Tudor Jones first reported a position in Clovis Oncology, Inc. in Q3 2015 and held it in 11 quarters.
Paul Tudor Jones's Clovis Oncology, Inc. position peaked at $7.88M in Q4 2015.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Tudor Investment Corp's 13F filing for Q2 2022, filed 15 Aug 2022.